Please login to the form below

Not currently logged in
Email:
Password:

darapladib

This page shows the latest darapladib news and features for those working in and with pharma, biotech and healthcare.

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK takes anti-inflammatory drug into phase III as heart therapy

GSK's cardiovascular pipeline suffered a setback last month when coronary artery disease therapy darapladib failed a second phase III trial.

Latest news

  • Second darapladib failure disappoints GSK Second darapladib failure disappoints GSK

    Drug unable to demonstrate effectiveness in acute coronary syndrome. Prospects for GlaxoSmithKline's coronary artery disease therapy darapladib have all but disappeared after it failed to show efficacy in a second ... Top-line results from the SOLID-TIMI

  • Moving parts Moving parts

    Meanwhile, costly phase III failures arrived in the shape of Lilly's depression drug edivoxetine and GlaxoSmithKline's highly anticipated new coronary heart disease drug candidate darapladib, which both flunked

  • GSK hit as darapladib flunks phase III test GSK hit as darapladib flunks phase III test

    Heart disease drug disappoints in late-stage trial.  . GlaxoSmithKline's highly anticipated new coronary heart disease (CHD) drug candidate darapladib has disappointed in a phase III trial. ... will continue to examine the data and wait for the results

  • GSK's Chinese sales hit by scandal, say analysts GSK's Chinese sales hit by scandal, say analysts

    darapladib for atherosclerosis which could have "vast potential" if it reaches the market.

  • GSK submits albiglutide for European approval GSK submits albiglutide for European approval

    Albiglutide is, along with lupus treatment Benlysta and heart disease drug darapladib, one of a trio of drugs GSK has developed with Human Genome Sciences.

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals during July 2012 Pharma deals during July 2012

    These are Benlysta (belimumab), an antibody approved for the treatment of lupus; darapladib, a phase III small molecule drug for the treatment of cardiovascular disease; and albiglutide, an albumin-fusion protein ... There is $150m in potential licence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
COUCH Health

We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...

Latest intelligence

The power of communication: Engaging diverse groups in healthcare
Humans are diverse and communications to engage us need to be inclusive. It’s no longer about talking to a group, a cohort or an imagined section of society - especially...
Building the hospital of the future
Senior Consultant Leah Carlisle explores the growing trend of virtual hospitals and what it takes to develop a holistic digital ecosystem centered on the ultimate patient experience....
Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....